Intuitive Surgical (NASDAQ:ISRG) -- recommended in Rule Breakers -- reported an 18.5% rise in Q2 revenue YOY, with a diluted earnings-per-share (EPS) rise of 26.5% coming in ahead of expectations, as the company reached 11,710 installations of its da Vinci robotic surgery platform. Management now expects a rise near the midpoint of the 13.5% to 15.5% range in da Vinci procedures for the full year, slowing from 18% in 2025 -- and that's playing on investor sentiment, with the stock down 10% in early morning trading.
- "Intuitive is still relatively early in the rollout of the da Vinci 5": Team Rule Breakers last month described Intuitive's latest technology generation as "a computation-heavy platform that is collecting a wealth of proprietary data on virtually every nuance of a surgeon's movements," and highlighted the stock's valuation was historically low at around 49 times trailing earnings -- though not traditionally cheap. It's about 47 now.
- "Changes in patient coverage and premium dynamics may be affecting when patients seek care": CEO David Rosa noted possible delays in seeking treatment, adding, "as patients return to care, we expect da Vinci will remain a clear choice for their surgeons and care teams."